- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06287203
Novel Prevention Intervention Program to Reduce Risky Patterns of Substance Use Among Emerging Adults (ARFP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There has been tremendous advances in gene identification. From large-scale, well-powered genome wide association studies (GWAS), polygenic scores (PGS) can now be calculated that sum risk alleles across the genome and weight them by their effect size, creating an index of genetic liability for any given individual. But genetic influences are only part of what contributes to substance use disorders; the environment also plays a critical role. Accordingly, understanding the development of substance use outcomes necessitates integrating both genetic and environmental information. The rationale for this line of research is that the integration of genetic and environmental information will provide the foundation for precision medicine, and that the provision of this personalized risk information will help prevent the development of problems and/or allow for earlier intervention before problems have become severe. Our research team is creating a new prevention/intervention program, consisting of an on-line platform for individuals to receive their personalized risk estimates for addiction risk, created by integrating information about their genetic, behavioral, and environmental risk factors followed by information about how to reduce risk.
The investigators are enrolling a sample of emerging adults (18-25 years of age) into a randomized controlled trial consisting of 4 conditions. All four conditions will involve completion of a behavioral/environmental risk survey and the provision of saliva to determine genetic risk. Three active conditions involve individuals receiving their personalized risk estimates, followed by (condition 1) psychoeducation about ways to reduce substance use and associated harm; (condition 2) the on-line CBT-based module to assist with controlling substance use; or (condition 3) a follow-up appointment with a genetic counselor (GC). The fourth condition will be a waitlist control, in which individuals will receive psychoeducation only at the time that the active conditions receive their personalized risk estimates.
At the first time point (T0), participants will be randomly selected into one of four conditions. Participants have an equal chance of being assigned to any one of the conditions. Across all conditions, the investigators will measure substance use and problems at enrollment (T0), at the time of receipt of risk estimates (~8 weeks later; or at the time other participants receive their results (~8 weeks later) in the case of control condition) (T1), 1 month (T2), and 3 months (T3) after completion of the program.
After the final survey (T3), participants in the control condition will receive their personalized risk estimates. All participants, regardless of their initial group, will be invited to receive access to the content of conditions in which they did not take part (e.g., online modules, appointment with a genetic counselor).
Findings from this study have great potential to enhance our ability to use precision medicine to prevent the development of substance use disorders and/or intervene earlier in the progression to disorder.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emily Balcke
- Phone Number: 732-235-5607
- Email: dnadiscoverystudy@rutgers.edu
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- Recruiting
- Rutgers Robert Wood Johnson Medical School
-
Contact:
- Emily Balcke
- Email: dnadiscoverystudy@rutgers.edu
-
Principal Investigator:
- Danielle Dick, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- This study is for emerging adults between 18-25 years who reside in the United States. These individuals must also be English-speaking.
Exclusion Criteria:
- Participants will be excluded from the study if they are younger than 18 years old, older than 25 years old, reside outside of the United States, or if they do not provide informed consent. These exclusion criteria have been chosen because we are targeting emerging adults (a particularly risky population in terms of substance use behaviors).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Risk estimates + Psychoeducation
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by psychoeducation about ways to reduce substance use and associated harm.
|
This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program).
The information in part 2 of the program will vary between arms.
|
Active Comparator: Risk estimates + Online CBT Modules
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by on-line cognitive behavioral therapy (CBT)-based modules to assist with controlling substance use.
|
This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program).
The information in part 2 of the program will vary between arms.
|
Active Comparator: Risk estimates + Genetic Counselor
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by a follow-up appointment with a genetic counselor.
|
This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program).
The information in part 2 of the program will vary between arms.
|
Other: Waitlist Control - Psychoeducation Only
Participants in this condition will not receive their personalized risk estimates until the end of the study.
They will receive psychoeducation about ways to reduce substance use and associated harm at the time that the active conditions receive their estimates and associated follow-up content.
|
This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program).
The information in part 2 of the program will vary between arms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol Consumption
Time Frame: 3 months
|
Alcohol consumption will be measured using the Alcohol Use Disorders Identification Test (AUDIT) consumption subscale.
The AUDIT-C consists of 3 items (e.g., "how often do you have a drink containing alcohol").
Items are rated on a 5-point scale.
Items will be summed to create subscale totals with higher scores representing higher levels of that behavior (e.g., higher alcohol consumption.
Scores can range from 0 to 12.
|
3 months
|
Alcohol Problems
Time Frame: 3 months
|
Alcohol problems will be measured using the AUDIT problems subscale ( Bohn, Babor, & Kranzler, 1995).
The AUDIT-P consists of 6 items (e.g., "how often do you have a drink containing alcohol").
Items are rated on a 5-point scale.
Items will be summed to create subscale totals with higher scores representing higher levels of that behavior (e.g., higher alcohol problems).
Scores can range from 0 to 24.
|
3 months
|
Drug Use Problems
Time Frame: 3 months
|
Drug Use problems will be measured using the Drug Use Disorders Identification Test (DUDIT) scale.
The DUDIT consists of 11 items (e.g., "how often do you use drugs other than alcohol").
Items are rated on a 5-point scale.
Items will be summed to create subscale totals with higher scores representing higher levels of that behavior (e.g., higher drug consumption).
Scores can range from 0 to 44.
|
3 months
|
Readiness to change
Time Frame: 3 months
|
The Readiness to Change Questionnaire is a 12-item measure that provides scores for three subscales (Precontemplation, Contemplation, and Action) representing stages of change.
Items (e.g., "I am trying to drink/ use other drugs less than I used to") are rated on a 5-point scale with response options ranging from "strongly disagree" to "strongly agree."
Items will be summed to create three total subscale scores.
Based on subscale scores, individuals will be categorized to one of the three categories.
We will assess change in the percent of individuals in each category.
|
3 months
|
Future substance use intentions
Time Frame: 3 months
|
Future substance use intentions will be assessed with three items: "how often do you plan to drink alcohol next month," "how often do you plan to get drunk next month," and "how often do you plan to use drugs next month" with response options of "less than last month," "the same as last month," and "more than last month."
We will assess change in the percent of individuals in each category (less, same, more than last month) for all three items.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Worry About Substance Use Disorders
Time Frame: Baseline to 3 months
|
An adapted version of the Cancer Worry Scale will be used to assess worry about developing substance use disorders within the past 30-days.
The scale consists of 8 items (e.g., "How often do you worry about developing alcohol or other drug use disorder?")
rated on a 4-point scale.
Items will be summed to create a total scale score with higher scores reflecting higher levels of worry about substance use disorders.
|
Baseline to 3 months
|
Perceived Susceptibility
Time Frame: 3 months
|
Perceived susceptibility of developing alcohol use or other drug use disorder will be assessed using the Health Beliefs about Mental Illness Instrument (Saleeby, 2000).
The scale consists of 5-items (e.g., "my chances of having alcohol or other drug problems are great") rated on a 5-point scale with response options ranging from "strongly agree" to "strongly disagree."
Items will be summed to create a total scale score with higher scores reflecting higher perceived susceptibility for substance use disorders.
|
3 months
|
Well-Being
Time Frame: 3 months
|
Well-being will be assessed with the Mental Health Continuum-Short Form.
The scale consists of 14-items which assess aspects of positive mental health (e.g., "I felt happy") over the past 30-days.
The items are rated on a 6-point scale with response options ranging from "never" to "every day."
Items will be summed to create a total scale score with higher scores reflecting higher levels of positive well-being
|
3 months
|
Anxiety and Depressive Symptoms
Time Frame: Baseline to 3 months
|
Abbreviated scales from the Symptom Checklist-90 will be used to assess anxiety and depressive symptoms occurring within the past 30-days.
The anxiety (e.g., "nervousness or shakiness inside") and depressive symptoms (e.g., "feeling no interest in things) subscales consist of four items each.
Items are rated on a 5-point Likert-type scale with response options ranging from "not at all to "extremely."
Items will be summed to create total subscale scores with higher scores reflecting higher levels of anxiety and depressive symptoms.
|
Baseline to 3 months
|
Addiction Risk Program Satisfaction
Time Frame: immediately after the intervention
|
Satisfaction with the addiction risk program will be assessed with 12 items after participants receive their personalized risk estimates.
Example items include "I learned new information as part of this program," "I enjoyed receiving my personalized risk profile," and "The online delivery method of the information was convenient."
The items are rated on a 5-point scale with response options ranging from "strongly agree" to "strongly disagree."This
will only be administered to the three active interventions.
|
immediately after the intervention
|
Feelings About Results
Time Frame: immediately after the intervention
|
Feelings about receiving results will be assessed with an adapted version of the Feelings About Genomic Testing Results Questionnaire. 10 items will be used to measure how participants feel about their personalized risk estimates.
The items will be rated on a 5-point scale with response options ranging from "not at all" to "a great deal."
Items will be summed to create a total scale score, with higher scores reflecting more positive feelings about receiving genetic test results.
This will only be administered to the three active interventions.
|
immediately after the intervention
|
Satisfaction with the Assigned Conditions
Time Frame: 3 months
|
Satisfaction with the three conditions (psychoeducation, CBT, and genetic counseling) will be assessed with 10 items.
Beyond the name of the condition referred to in each of the items ("education content," "modules," and "genetic counseling", respectively) the satisfaction items are the same for each of the three conditions (e.g., "I learned useful information as part of the modules").
The items are rated on a 5-point scale with response options ranging from "strongly agree" to "strongly disagree."
The satisfaction items will be administered to the waitlist control in the T1part 2 survey, and it will be administered to the three active conditions in the T2 and T3 follow-up surveys.
If the participant completed the satisfaction items at T2, they will not receive them again at T3.
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Danielle Dick, PhD, Rutgers Robert Wood Johnson Medical School
Publications and helpful links
General Publications
- Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995 Jul;56(4):423-32. doi: 10.15288/jsa.1995.56.423.
- Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res. 2005;11(1):22-31. doi: 10.1159/000081413.
- Custers JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs. 2014 Jan-Feb;37(1):E44-50. doi: 10.1097/NCC.0b013e3182813a17.
- Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14.
- Dar-Nimrod I, Zuckerman M, Duberstein PR. The effects of learning about one's own genetic susceptibility to alcoholism: a randomized experiment. Genet Med. 2013 Feb;15(2):132-8. doi: 10.1038/gim.2012.111. Epub 2012 Aug 30. Erratum In: Genet Med. 2013 May;15(5):412.
- Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull. 1973 Jan;9(1):13-28. No abstract available.
- Keyes CLM. Brief description of the mental health continuum short form (MHC-SF). 2009. http://www.sociology.emory.edu/ckeyes/
- Heather N, Rollnick S, Bell A. Predictive validity of the Readiness to Change Questionnaire. Addiction. 1993 Dec;88(12):1667-77. doi: 10.1111/j.1360-0443.1993.tb02042.x.
- Saleeby JR. Health beliefs about mental illness: An instrument development study. American Journal of Health Behavior. 2000;24(2):83-95.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro2023001498
- 3R01DA050721-04S1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingSubstance Use | Substance Use Disorders | Substance DependenceUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Opioid Use | Drug Use | Substance MisuseUnited States
-
Istanbul UniversityCompletedSubstance Use | Substance Use Disorders | Substance AbuseTurkey
-
Centre for Addiction and Mental HealthUniversity of Missouri, St. LouisCompletedSubstance Use Disorders | Alcohol Use DisorderCanada
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedPTSD | Alcohol Use Disorders | Substance Use DisordersUnited States
Clinical Trials on Addiction Risk Feedback Program
-
Boston UniversityNational Human Genome Research Institute (NHGRI)Completed
-
In-Home Addiction Treatment Institute, Inc.Suspended
-
George Mason UniversityOAR, Fairfax; Slonky, IncUnknownSubstance Use | HIV Risk Behavior
-
Wake Forest University Health SciencesCompleted
-
Children's Hospital Medical Center, CincinnatiSeattle Children's Hospital; St. Jude Children's Research Hospital; University...RecruitingCancer | Adherence, MedicationUnited States
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of Rhode IslandCompleted
-
Clinique Romande de ReadaptationCompletedStroke | Multiple Sclerosis | Cerebral Palsy | Parkinson Disease | Spinal Cord Injuries | People With Impaired Lower Extremity FunctionSwitzerland
-
Khon Kaen UniversityCompletedSpinal Cord InjuriesThailand
-
US Department of Veterans AffairsCompletedAdverse Drug EventsUnited States